News

NewAmsterdam Pharma's Upcoming Conference Participation for 2024

NewAmsterdam Pharma's Upcoming Conference Participation for 2024

NewAmsterdam Pharma Announces Conference Participation

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in the healthcare community.

Key Presentations at the 2024 AHA Scientific Sessions

At the upcoming 2024 American Heart Association (AHA) Scientific Sessions, NewAmsterdam will present significant safety and efficacy data from its pivotal Phase 3 BROOKLYN study. This research focuses on obicetrapib, a promising treatment for patients suffering from Heterozygous Familial Hypercholesterolemia, a genetic condition characterized by high levels of low-density lipoprotein cholesterol (LDL-C).

Details of the Presentation

Scheduled for November 18, 2024, the presentation will discuss the following aspects:

  • Title: Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (BROOKLYN)
  • Session Title: Late-Breaking Science 8: New Targets and New Treatments: Advances in Lipid Therapeutics
  • Presenter: Stephen Nicholls, M.B.B.S., Ph.D., a renowned expert from Monash University

Participation in the Jefferies London Healthcare Conference

NewAmsterdam will also take part in the Jefferies London Healthcare Conference from November 19-21, where management will discuss the company's advancements and future directions in cardiovascular therapies.

Conference Highlights

The fireside chat, happening on November 21, 2024, will feature:

  • Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam
  • John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer
  • Ian Somaiya, Chief Financial Officer

Innovative Development of Obicetrapib

Obicetrapib stands out as a unique oral, low-dose CETP inhibitor designed to enhance the treatment landscape for patients facing cardiovascular risks. Through a robust series of clinical trials, including Phase 2 studies like ROSE2, TULIP, ROSE, and OCEAN, NewAmsterdam has demonstrated not only significant LDL-lowering effects but also a safety profile resembling that of a placebo.

Continued Clinical Trials and Research

The company is actively engaging in additional trials to validate obicetrapib's effectiveness:

  • BROADWAY Trial: Investigates obicetrapib as an adjunct to maximal lipid-lowering therapies.
  • TANDEM Trial: Studies the combination of obicetrapib and ezetimibe as a fixed-dose treatment.
  • PREVAIL Trial: Focused on assessing cardiovascular outcomes, enrolling more than 9,500 participants.

Commitment to Patients with Metabolic Diseases

NewAmsterdam's mission is to tackle the unmet needs for safe and effective therapies in the management of metabolic diseases. The company aims to bring its oral, once-daily CETP inhibitor to various markets, catering specifically to patients who have been underserved by existing treatment options.

Partnering for Success

The commercialization rights for obicetrapib within Europe have been granted to the Menarini Group, an experienced international pharmaceutical organization. This strategic partnership underscores NewAmsterdam's commitment to ensuring that its innovative therapies reach those who need them most.

Stay in Touch with NewAmsterdam

As NewAmsterdam prepares for these significant upcoming events, stakeholders and interested parties should feel free to reach out for more information or engage with the company through the following contacts:

Company Contact

Matthew Philippe
P: 1-917-882-7512
Email: matthew.philippe@newamsterdampharma.com

Media Contact

Spectrum Science on behalf of NewAmsterdam
Bryan Blatstein
P: 1-917-714-2609
Email: bblatstein@spectrumscience.com

Investor Contact

Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
Email: austin.murtagh@precisionaq.com

Frequently Asked Questions

What is the primary focus of NewAmsterdam Pharma's research?

NewAmsterdam Pharma focuses on developing novel oral therapies aimed at lowering LDL cholesterol levels in patients at risk of cardiovascular disease.

When will the AHA presentation on obicetrapib occur?

The presentation is scheduled for November 18, 2024, during the AHA Scientific Sessions.

Who will present at the Jefferies London Healthcare Conference?

Key presentations will be made by Chief Executive Officer Michael Davidson, Chief Scientific Officer John Kastelein, and Chief Financial Officer Ian Somaiya.

What is the significance of obicetrapib?

Obicetrapib is being developed as a lower-risk treatment option with a promising efficacy profile for patients with familial hypercholesterolemia.

How does NewAmsterdam Pharma engage with investors?

NewAmsterdam provides regular updates through conferences, investor relations webcasts, and communications from their investor contact.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AI Use Hits 93% in Health Systems' Digital Shift

Updated Category News Views 33

Healthcare's AI Surge: Jumping the Adoption Hurdle The digital health landscape isn't just humming along—it's hitting high gear. AI, once the shiny toy in innovation's toolkit, is now a fixture in 93.2% of healthcare systems according to CHIME's latest findings. For anyone keeping score, that's a hefty leap and paints a picture where AI isn't just in the game, it's...

Continue Reading
Dana Concludes Tender Offers for Senior Notes

Updated Category News Views 72

An Investor's Glance at Dana's Strategic Moves Dana Incorporated (NYSE: DAN) just pulled a bold move with their tender offers, snapping up a hefty $357,873,000 in outstanding principal on their senior notes. This isn’t just pocket change; folks holding out for securities can feel the tension of watching big numbers get shuffled around. You gotta wonder, what's the play...

Continue Reading
Later's NYC Summit Reinvents Social Commerce Game Plan

Updated Category News Views 120

Creators and Corporates Collide Imagine this: an NYC stage not adorned with Broadway's finest, but with digital maestros steering a new age in social commerce. That's what Later is betting on with their Creator Live summit, debuting in the bustling heart of New York City. We're talking about influencers not just as Instagram stars, but as key players in a $480 billion...

Continue Reading
Koppers Faces SEC Scrutiny After Earnings Miss

Updated Category News Views 124

Koppers' Third-Quarter Blues: Missing the Mark Koppers Holdings Inc. (NYSE: KOP) took a hard hit this quarter, missing Wall Street's earnings expectations by a mile. The adjusted earnings per share came in at just $0.77, while the suits down on Wall Street were expecting something closer to $1.34 to $1.37. Now, if you’re holding KOP in your portfolio, you're probably...

Continue Reading
National Police Assoc. Urges House to Pass PTSD Act

Updated Category News Views 101

An Urgent Call for Action on PTSD Support Alright folks, this ain't your typical investment rundown, but it's got stakes just the same. The National Police Association is sounding the horn for the House to pass the Fighting Post-Traumatic Stress Disorder Act of 2025 (S. 825). Now, if you've been around the block, you know legislation can play out like a market...

Continue Reading
CR&R Workers Join Teamsters, Fight for Fair Conditions

Updated Category News Views 74

Waste Workers Push Back Against Corporate Pressure The Southern California sun isn't the only thing heating up these days; the waste workers at CR&R Environmental Services have cranked up the heat by voting to join Teamsters Local 396. It's like Groundhog Day in the world of labor rights—same story, different locale, workers banding together for a fair shot. A Stand...

Continue Reading
SOCSA: The Future of Safety in Confined Spaces?

Updated Category News Views 68

Autonomous Tech Meets Safety Regulations Some days innovation hits like a ton of bricks, and here we go again—this time with a gizmo aiming to shake up the safety game in confined spaces. Enter the SOCSA, the Self Operating Confined Space Attendant, designed by a seasoned agriculture worker who's had a ringside seat to enough OSHA rule breaches to fill a book. But ain't...

Continue Reading
Accuray Finishes Key Deal, Resetting Financial Trajectory

Updated Category News Views 112

Accuray Secures the Deal, But Is the Future Bright? Every now and then in the investing world, a company pulls off a maneuver that you wish you’d thought of first. Today, folks, it's Accuray's turn. They've just wrapped up a monstrous transaction with TCW – their primary lender and shareholder – that has them feeling optimistic about the road ahead. Bold Moves to...

Continue Reading
Citigroup, Scotia Aid TSTT in $500M Note Offering

Updated Category News Views 49

Kicking off with a banger that’s got financial water coolers buzzing, Greenberg Traurig just pulled a rabbit out of the hat helping Citigroup and Scotia Capital orchestrate a chunky near $500 million dual-currency notes deal for Telecommunications Services of Trinidad and Tobago Limited (TSTT). Now, this isn’t your run-of-the-mill market maneuver. We're seeing a...

Continue Reading
Agiloft Navigates New Growth Phase with Key Leadership

Updated Category News Views 142

Leadership Shifts Steer Agiloft's EMEA Journey Agiloft's latest shake-ups in leadership signal a determined charge through EMEA's bustling markets. Nick Bowles, a seasoned veteran in enterprise software, steps into the limelight as Senior Vice President, while Jim Leason shifts gears into a customer-focused advisory role. These aren’t just routine hiring...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Innovative Glaucoma Research with 2025 Grants Announcement

Updated Category News Views 283

2025 Shaffer Grants Foster Groundbreaking Glaucoma Research In an exciting development in the field of ophthalmology, the Glaucoma Research Foundation (GRF) has revealed its nine recipients of the prestigious 2025 Shaffer Research Grants, totaling $55,000. These grants are designed to support innovative research aimed at understanding and potentially transforming...

Continue Reading
Beyond Air's Participation in Upcoming Investment Conference

Updated Category News Views 141

Beyond Air to Engage at H.C. Wainwright Conference Beyond Air, Inc. (NASDAQ: XAIR), a pioneering biopharmaceutical company known for its innovative approach to medical devices, recently declared its commitment to participate in the H.C. Wainwright 27th Annual Global Investment Conference. Steve Lisi, the Chairman and Chief Executive Officer, will represent the company at...

Continue Reading
Investors Urged to Act on Sable Offshore Corp. Securities Case

Updated Category News Views 150

Investors Now Have an Important Opportunity with Sable Offshore Corp. In light of recent developments, investor awareness regarding Sable Offshore Corp. (NYSE: SOC) has become crucial. Allegations of securities fraud have emerged, prompting a thorough investigation led by the DJS Law Group. This investigation centers around potential violations of securities laws, raising...

Continue Reading
Coeur Mining Prepares for Q4 and Full-Year 2024 Earnings Results

Updated Category News Views 131

Coeur Mining Earnings Report Announcement Coeur Mining, Inc. (NYSE: CDE) is gearing up to release its operational and financial outcomes for the fourth quarter and the full year of 2024. This report is poised to be made public following the close of the New York Stock Exchange on a specified date. Following the announcement, Coeur will host a conference call to discuss...

Continue Reading
Exploring Option Care Health's Robust Financial Victory for 2024

Updated Category News Views 85

Financial Overview of Option Care Health Option Care Health, Inc. (NASDAQ: OPCH), recognized as the largest independent provider of home and alternate site infusion services, recently shared its financial results for the fourth quarter and the entirety of 2024. Their performance reflects strategic execution and strong market demand despite a challenging environment....

Continue Reading